pCODR gives initial positive recommendation for Ovarian Cancer Drug

pCODR recently announced their initial positive recommendation for Olaparib (Lynparza), a targeted therapy for ovarian cancer.

As part of their recommendation, pCODR stated that “Reimbursement should be for olaparib monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic as detected by approved testing) high grade serious epithelial ovarian, fallopian tube, or primary peritoneal cancer who have completed at least two previews lines of platinum-based chemotherapy and are in radiologic response (complete or partial response) to their most recent platinum-based chemotherapy regimen.

To read the complete recommendation, please click here.